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Prepulse inhibition (PPI) of startle occurs when intensity stimuli precede stronger
startle-inducing stimuli by 10–1000ms. PPI deficits are found in individuals with
schizophrenia and other psychiatric disorders, and they correlate with other cognitive
impairments. Animal research and clinical studies have demonstrated that both PPI and
cognitive function can be enhanced by nicotine. PPI has been shown to be mediated, at
least in part, by mesopontine cholinergic neurons that project to pontine startle neurons
and activate muscarinic and potentially nicotine receptors (nAChRs). The subtypes
and anatomical location of nAChRs involved in mediating and modulating PPI remain
unresolved. We tested the hypothesis that nAChRs that are expressed by pontine startle
neurons contribute to PPI. We also explored whether or not these pontine receptors
are responsible for the nicotine enhancement of PPI. While systemic administration of
nAChR antagonists had limited effects on PPI, PnC microinfusions of the non-α7nAChR
preferring antagonist TMPH, but not of the α7nAChR antagonist MLA, into the PnC
significantly reduced PPI. Electrophysiological recordings from startle-mediating PnC
neurons confirmed that nicotine affects excitability of PnC neurons, which could be
antagonized by TMPH, but not by MLA, indicating the expression of non-α7nAChR. In
contrast, systemic nicotine enhancement of PPI was only reversed by systemic MLA
and not by TMPH or local microinfusions of MLA into the PnC. In summary, our data
indicate that non-α7nAChRs in the PnC contribute to PPI at stimulus intervals of 100ms or
less, whereas activation of α7nAChRs in other brain areas is responsible for the systemic
nicotine enhancement of PPI. This is important knowledge for the correct interpretation of
behavioral, preclinical, and clinical data as well as for developing drugs for the amelioration
of PPI deficits and the enhancement of cognitive function.
Keywords: prepulse inhibition, sensory gating, sensorimotor gating, startle, rat, schizophrenia, nicotine receptor,
alpha-7 nicotine receptor
INTRODUCTION
Prepulse inhibition (PPI) describes the attenuation of a reflexive
motor response due to the presentation of a sensory stimu-
lus prior to the response eliciting stimulus, and can be easily
measured in humans and animals using the acoustic startle
response. Sensory processing of e.g., the prepulse is facilitated
when colliculus-mediated orienting responses occur, leading to
inhibition of the startle pathway at the same time. In particular,
mesopontine cholinergic arousal systems provide diffuse thala-
mocortical activation while inhibiting startle (Fendt et al., 2001;
Yeomans, 2012). PPI disruptions are a hallmark of schizophrenia,
but PPI is also disrupted in several other neurological disorders
(for review see Powell et al., 2012; Kohl et al., 2013; Swerdlow,
2013), and PPI disruptions are correlated with other cognitive
dysfunctions, such as disorganized thought, attention deficits and
working memory disruptions (Braff et al., 1978; Geyer and Braff,
1987; Young et al., 2009; Singer et al., 2013).
The mesopontine cholinergic projection from the pedun-
culopontine and laterodorsal tegmentum (PPT/LDT) to the
startle mediating giant neurons in the caudal pontine retic-
ular nucleus (PnC) has been identified as a crucial system
for inhibiting startle during PPI (for review see Koch, 1999;
Fendt et al., 2001). Lesions to the PPT/LTD severely attenuate
PPI in rats (Kodsi and Swerdlow, 1997; Jones and Shannon,
2004; but see MacLaren et al., 2014) and stimulation of
this projection activates muscarinic receptors inhibiting startle-
mediating giant neurons in the PnC (Bosch and Schmid, 2006).
In addition, there is evidence that ionotropic nicotine recep-
tors (nAChRs) contribute to this cholinergic effect (Bosch and
Schmid, 2008). In fact, the activation of both ionotropic and
metabotropic receptors have been suggested to mediate the
fast (10–100ms) and long-lasting (100–1000ms) effects of PPI,
respectively (Jones and Shannon, 2000a; Yeomans et al., 2010).
Thus, pontine nAChRs might play a role in mediating PPI
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especially at shorter intervals between prepulses and startle
stimuli.
Systemic administration of nicotine has also been shown to
enhance PPI in healthy human participants (Warburton, 1992;
Warburton et al., 1992; Kumari et al., 1996; Della Casa et al.,
1998; Levin et al., 1998b; Mancuso et al., 1999; Levin and Rezvani,
2006), in individuals with schizophrenia (Kumari et al., 2001;
Postma et al., 2006; Hong et al., 2008), and in rodents (Acri et al.,
1994; Curzon et al., 1994; Levin et al., 1998a; Faraday et al., 1999;
Azzopardi et al., 2013). It is not known if nicotine affects PPI
directly within the PnC, or indirectly by modulating neuronal
activity in higher brain regions that exert modulatory control over
the startle and PPI circuitry, such as the hippocampus, striatum,
medial prefrontal cortex, or amygdala (for review see Koch, 1999).
In this study we tested the hypothesis that the activation
of nAChRs located in the PnC contributes to PPI, particu-
larly at short interstimulus intervals, using systemic and local
PnC microinfusions of nAChR antagonists and agonists in
rodents. Subsequently, following the identification of the nAChR
subtype(s) involved, using behavioral and electrophysiological
approaches, we tested whether or not the same nAChRs are
responsible for the systemic nicotine enhancement of PPI.
MATERIALS AND METHODS
BEHAVIORAL EXPERIMENTS
Animals
Male adult Sprague Dawley rats, weighing 250–350 g, were
obtained from Charles River Canada (St. Constant, QC, Canada).
Adult rats were housed in groups of two or three (except during
recovery period after surgery) at a temperature of 21 ± 1◦C in
individual cages on a 12 h light/dark cycle with lights on at 7 a.m.,
and food and water available ad libitum. All animal procedures
were approved by the University of Western Ontario Animal Care
Committee and followed the guidelines of the Canadian Council
on Animal Care. All efforts were made to minimize the num-
ber of animals used and any discomfort resulting from surgical
or behavioral procedures. Testing occurred during the light part
of the light/dark cycle to minimize movement during testing in
these nocturnal animals.
Surgery
For local microinfusions into the PnC, rats were anaesthetized,
using a mixture of 2% isoflurane and 98% oxygen. A subcuta-
neous injection of 0.05mg/kg of buprenorphine and 5mg/kg of
ketoprofen was given during surgery for analgesia. Blunt-ended
ear bars and a snout mask were used to secure the head in the
stereotaxic device. Two 23-gauge stainless steel guide cannulae
(Plastics One, Roanoke, VA, USA) were stereotaxically aimed
bilaterally at the ventrocaudal segment of the PnC based on coor-
dinates derived from the Paxinos and Watson rat brain atlas
(Paxinos and Watson, 2005). Coordinates relative to Lambda
were: +2.5mm in the medial/lateral plane; −8.80mm in the
ventral/dorsal plane; −2.1mm in the rostral/caudal plane, with
a 10 degree mediolateral angle. The cannulae were mounted
on the skull with dental cement casted around four jeweler’s
screws implanted bilaterally into the parietal skull plates. Stainless
steel stylets were inserted into cannula to prevent clogging
(PlasticsOne, Roanoke, VA, USA). Silk suture was used to close
the wound, and rats were allowed a 7-day recovery period in the
animal care facility.
Handling
Approximately 3 days before testing, rats were handled to ensure
familiarity with the handler and the startle boxes. Rats were
socialized for approximately 10min each day for 3 days. On the
second and third handling days, rats were afterwards placed in
the startle apparatus for 5–10min while the constant sound of a
65 dB white noise played in the background.
Injections/microinfusions
Each rat received two systemic injections or local microinfusions
unless otherwise noted: one drug and one vehicle, in a pseudo-
randomized order and at least 5 days apart. Stereotaxic microin-
fusions were accomplished with 30 G Infusion cannulae that were
inserted into the guide cannulae and extended 1mm beyond the
tip of the guide cannulae. 0.5μL of drug or vehicle was injected
bilaterally in awake rats over a 4-min period, using a mechan-
ical syringe pump (World Precision Instruments, Sarasota, FL).
Infusion cannulae remained inside the guide cannulae for an extra
minute to ensure complete diffusion of drug.
Startle testing
After injections or microinfusions, rats went back to their home
cage and were placed in startle chambers (Med Associates,
Vermont, USA) 5–20min after injection, unless otherwise noted.
The startle reflex software SOF-825, version 5.95 (Med Associates,
Vermont, USA) was used to perform experiments and analyze
data. Rats were first subjected to a 5min acclimation period with a
65 dB white noise background without further stimulation. They
were then exposed to 30 pulse-alone trials (Block 1) for habitu-
ation. Immediately following Block 1, they were subjected to up
to 60 pseudo-randomized trials consisting of different stimula-
tion trials, each administered 10 times (Block 2): a pulse-alone
trial, and up to five different prepulse-pulse trials with the fol-
lowing Interstimulus intervals (ISI) between prepulse and startle
pulses: 12, 20, 50, 100, and/or 250ms. The startle evoking pulse
always consisted of a 20ms long burst of white noise of 105 dB.
Two different prepulse intensities, either 75 or 85 dB, were used
as indicated. All prepulses consisted of a 4ms long burst of white
noise. Trials were 20 s apart. For a more detailed description, see
(Valsamis and Schmid, 2011). Protocols were shortened by omit-
ting trial types in experiments involving injections of nicotine,
since nicotine has a short half-life.
Histology
Rats that had received microinfusion through cannula implants
were injected with a lethal dose of pentobarbital and received a
microinfusion of a small amount of 3% thionine dye through
the implanted cannulae in order to mark placements. Rats were
then perfused transcardially. Brains were harvested and post-
fixed by immersion in 4% paraformaldehyde (PFA) for at least
1 h, and then transferred to 15% sucrose (in buffer) for another
24 h. Brains were sliced into 50μm-thick sections by a freezing
microtome. Sections were mounted, dried, and stained using the
Haematoxylin and Eosin counterstaining procedure. Cannulae
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coordinate determination was made using a rat brain atlas by
Paxinos and Watson (2005). Microinfusion tips that reached or
penetrated the borders of the PnC were deemed as successful hits.
All other placements were deemed as misses and their data were
discarded.
Data analysis
The 10 startle responses that were preceded by a specific prepulse
were averaged and divided by the average startle responses that
had no preceding prepulse in block 2. These numbers were then
subtracted from 1 and multiplied by 100 to yield a “Percent PPI”
score:
% prepulse inhibition =(
1 −
(
prepulse − pulse trial amplitude)(
pulse − alone trial amplitude)
)
∗ 100
Averages of both PPI intensities were taken for every ISI, and Two-
Way, repeated measures ANOVAs were conducted using GB Stat
software (GB Stat®). If warranted, a Fischer’s Least Significance
Difference (LSD) post-hoc test was used to assess points of signif-
icance. Baseline startle measurements were calculated by averag-
ing, for each rat, the first 30 startle alone trial responses in block 1.
These individual baseline startle scores were analyzed for different
drug conditions using a two-tailed, paired Student’s t-test. In both
the ANOVAs and the Student’s t-tests, differences in the data were
deemed significant if p-values were less than 0.05 (α = 0.05).
ELECTROPHYSIOLOGY
Slice preparation
A more detailed description of the slice preparation contain-
ing the PnC giant neurons and their afferent projections within
the startle pathway has been published previously (Weber et al.,
2002; Simons-Weidenmaier et al., 2006; Schmid et al., 2010, see
also Supplementary Figures S1, S2). In brief, juvenile Sprague-
Dawley rats (P9-14, with P1 defined as the day of birth) were
anaesthetized with isoflurane and their brains rapidly removed
and transferred into ice-cold preparation solution containing (in
mM): KCl, 2; MgCl2, 2; KH2PO4, 1.2; MgSO4, 1.3; NaHCO3, 26;
glucose, 10; saccharose, 210; CaCl2, 2; myoinositol, 3; sodium
pyruvate, 2; ascorbic acid, 0.4; equilibrated with 95% O2/5%
CO2. Coronal slices of 350–400μm thickness were cut with a
vibratome (Microm, Walldorf, Germany) in a submerged cham-
ber filled with ice-cold preparation solution and transferred into
a holding chamber filled with artificial cerebrospinal fluid (ACSF)
containing (in mM): KCl, 2; KH2PO4, 1.2; MgSO4, 1.3; NaHCO3,
26; NaCl, 124; glucose, 10. CaCl2 (2mM) was added a few min-
utes after slices had been transferred. In order to improve later
patch success the holding chamber was heated for 30min to 32–
35◦C. Slices were then kept at room temperature for at least an
additional 30min.
Electrophysiological recordings
For recording, slices were transferred into a superfusion recording
chambermounted on an upright microscope (Zeiss, Oberkochen,
Germany) with an infrared sensitive camera (Kappa, Germany).
Superfusion rate was 2–3ml ACSF/min at room temperature and
patch-clamp recordings have been carried out under visual guid-
ance. Patch electrodes were pulled out of borosilicate capillaries
(Science Products, Hofheim, Germany) and filled with a solu-
tion containing (in mM): K-gluconate, 130; EGTA, 0.5; MgCl2,
2; KCl, 5; HEPES, 10; pH 7.2 (KOH), 270–290 mosm. Electrodes
had a resistance of 2.3–3.5 M. The calculated junction poten-
tial using pClamp 10 is 11.8mV and data was not corrected
for it.
Giant neurons in the PnC were identified by a soma diameter
greater than 35μm and all recordings were made in voltage-
clamp mode at a holding potential of −70mV unless otherwise
noted. Resting membrane potentials were measured by briefly
switching into current clamp mode (I = 0). Presynaptic stimuli
were applied by bipolar tungsten electrodes (Science Products).
One stimulation electrode was positioned medial to the prin-
cipal sensory trigeminal nucleus (Pr5) and the seventh nerve
in order to stimulate trigeminal afferents. The second electrode
was positioned ventral to the lateral superior olive for auditory
afferent fiber stimulation. Both electrodes were connected via iso-
lators to a pulse generator (Master-8, Science Products). Stimulus
pulse duration was always 150μs. Stimulus intensities were kept
low to avoid spiking of the postsynaptic neurons. Recordings
were made using an Axopatch 200B amplifier and digitized by
Digidata 1200 (both Axon Instruments, Union City, USA). The
data was filtered with a 5 kHz low-pass filter, the sampling rate
was 20 kHz. The pClamp 8.2.0 software (Axon Instruments)
was used for data acquisition and analysis. Series resistance and
seal quality were monitored at the beginning and several times
throughout the recordings. Only one cell was recorded per slice,
and there was only one slice per rat in most cases. Statistical
analysis was performed using SPSS. When only one drug/dose
was tested, a Student’s t-test was perfomed, and the p-value is
reported. When several drugs or doses were tested, a repeated
measurement mixed design ANOVA was used and both F- and
p-values are reported. A LSD test was used for post-hoc analy-
sis. In both the ANOVAs and the Student’s t-tests, differences in
the data were deemed significant if p-values were less than 0.05
(α = 0.05).
DRUGS
The following drugs were used in behavioral and electrophysio-
logical experiment in concentrations as indicated in the Results
section: Liquid (−)-Nicotine (Sigma Chemical Co. Ltd., USA,
concentration reflects the free base), the cholinergic receptor
agonist carbachol (Sigma Chemical Co. Ltd., USA), the nat-
ural alkaloid and nicotine receptor blocker (+)-tubocurarine
chloride (Tocris Bioscience, USA), the natural alkaloid and
specific alpha-7 nicotine receptor blocker methyllycaconitine
(MLA; Tocris Bioscience, USA), the highly alpha-7 specific ago-
nist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-
carboxamide hydrochloride (PHA 543 613; Tocris Bioscience,
USA) and the non-α7 preferring non-competitive nAChR antag-
onist, 2,2,6,6-tetramethylpiperidin-4-yl heptanoate (TMPH)
hydrochloride (Tocris Bioscience, USA). Drugs were dissolved
in double distilled water in a 100X stock solution and kept
at −18◦C until used in behavioral experiments. Before usage,
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they were diluted in physiological saline. Drug concentrations
were selected based on previously published studies (nico-
tine: Hamann and Martin, 1992; Acri et al., 1994; Schreiber
et al., 2002; MLA: Panagis et al., 2000; Chilton et al., 2004;
TMPH: Damaj et al., 2005). For electrophysiological exper-
iments, drugs were dissolved in a 1000∗ stock solution in
double distilled water and they were added to the bath solu-
tion (1:1000) during experiments. Cadmium (100μM; Sigma-
Aldrich, Canada) was prepared as a 50mM CdCl2 stock
solution and added to the perfusing (oxygenated) ACSF to
block synaptic transmission by blocking voltage-gated calcium
channels.
RESULTS
SYSTEMIC NICOTINE ANTAGONISTS
In order to test the role of nAChRs in prepulse inhibition, we
systemically injected a group of 8 rats with the non-α7nAChR
preferring antagonist TMPH and the α7nAChR antagonist MLA,
at a dose of 10mg/kg which has been shown by others to be highly
effective (Damaj et al., 2005; Gao et al., 2010). Each rat received
both drugs and a vehicle injection in a pseudorandomized order,
and at least 5 days apart, for within subject comparison. Systemic
administration of nAChR antagonists did not alter PPI [F(2, 34) =
1.896; p = 0.200; Figure 1, top]. There was also no effect on
baseline startle amplitudes [F(2, 34) = 0.108; p = 0.200; Figure 1,
bottom].
NICOTINE AND nAChR ANTAGONISTS IN THE PnC
nAChRs are abundantly expressed and might mediate opposing
effects on PPI when targeted systemically. We therefore, targeted
nAChRs directly in the PnC where the mesopontine cholinergic
neurons supposedly synapse on startle mediating giant neurons,
using microinfusions through chronically implanted bilateral
cannulas prior to behavioral testing. Post-mortem histology con-
firmed PnC placement of cannulas for a group of 9 rats. Data
of 3 rats were discarded since one or both cannulas missed the
PnC. Intracranial (i.c.) microinfusions of 10mMnicotine (0.5μl)
revealed a main group effect of nicotine in these 9 rats [F(1, 17) =
67.06; p < 0.0001, Figure 2]. A LSD post-hoc analysis showed
that 5 nmol nicotine severely disrupted PPI at all tested ISIs (20,
50, and 100ms). Furthermore, the post-hoc analysis showed that
PPI disruption was significantly stronger at a short ISI of 20ms
compared to a longer ISI of 100ms. Baseline startle was not
affected by microinfusions of nicotine into the PnC (p = 0.34,
Figure 2).
Subsequently, we infused the α7nAChRs antagonist MLA and
the non-α7nAChRs preferring antagonist TMPH locally into the
PnC. At doses of 0.1, 1, and 8mM, MLA did not have any sig-
nificant effect on PPI at any ISI [F(3, 20) = 1.90; p = 0.15; n = 6
animals]. Baseline startle amplitudes were also not affected by
PnC microinfusions of MLA (p = 0.08; n = 6; Figure 3A). In
contrast, PnCmicroinfusions of TMPH hydrochloride at doses of
0.1, 1, and 10mM showed significant main group effects of drug
on PPI [F(3, 36) = 115.89; p < 0.0001; n = 10 animals] with post-
hoc analysis revealing significant attenuation of PPI for the 10mM
dose of TMPH at short ISIs of 20 and 50ms, and no significant
effect at ISIs of 100 and 250ms. Baseline startle was not affected
FIGURE 1 | Systemically injected nicotine antagonists do not affect
PPI. Prepulse inhibition was measured using a 75 or 85 dB white noise
prepulse preceding the startle pulse by different intervals, as indicated. The
amount of PPI was calculated using the intermingled trials without prepulse
as baseline startle (0% PPI). Rats were systemically injected with saline,
the α7nAChR preferring antagonist MLA, or the non-α7nAChR antagonist
TMPH at doses previously shown to be effective. There was no effect of
drug on PPI at prepulse levels of 75 dB (top), or 85 dB (middle). Baseline
startle amplitudes were analyzed during the habituation block (see
Materials and Methods; n = 8 rats per group).There was also no effect of
drug on the baseline startle response amplitude (bottom).
by PnC application of TMPH (p = 0.11; n = 10; Figure 3B). In
summary, microinfusions of nicotine antagonists into the PnC
indicate a role of non-α7nAChRs in mediating a part of total
PPI, specifically at short intervals between prepulse and startle
stimuli.
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FIGURE 2 | Local PnC microinfusions of 0.5μl nicotine (10mM) impair
PPI. Rats were bilaterally injected with 10mM nicotine (in 0.5μl saline) or
vehicle through chronically implanted cannulae targeting the PnC. They
were immediately tested for startle and PPI using a 75 db white noise
prepulse. The amount of PPI was significantly decreased in rats injected
with nicotine when compared to rats injected with saline (labeled by “a”).
The decrease was significantly stronger at 20ms interstimulus intervals
compared with 100ms intervals (labeled by “b”). Baseline startle
amplitudes did not significantly differ between groups (n = 9 rats).
EFFECTS OF NICOTINE ON PnC GIANT NEURONS IN BRAIN SLICES
In addition to PnC microinfusions of nicotine in vivo, we applied
nicotine in acute brain slices and monitored glutamatergic
synaptic transmission of sensory signaling from afferent startle
pathways as well as membrane properties in visually identified
startle-mediating PnC giant neurons (see Materials and Methods,
Supplementary Figures S1, S2, and Weber et al., 2002). As shown
in Figure 4A, bath application of 10μM nicotine significantly
reduced the amplitude of both presynaptically evoked trigemi-
nal and auditory synaptic currents to 79.4 ± 3.5% of control and
72.0 ± 4.2% of control, respectively (p < 0.001 and p < 0.001,
respectively; n = 14 cells). After subsequent washout of nicotine
EPSC amplitudes recovered to close to control levels (Figure 4C).
Paired-pulse ratios with 100ms IS were unchanged (1.52 ± 0.14
control, and 1.51 ± 0.08 during nicotine). Additionally, mem-
brane resistance was calculated by applying hyper- and depolariz-
ing 10mV voltage steps and measuring the resulting change in
whole cell (leak-) current according to Ohm’s law. Membrane
resistance of the analyzed PnC giant neurons was significantly
reduced during the application of nicotine to 61± 5.9%M from
an average of 245.14 ± 20.95 M under control condition to an
average of 124.92 ± 10.96M (p = 0.002; n = 14; Figure 4B).
This effect was also reversed by subsequent wash out (Figure 4C).
The holding current significantly increased from −143 ± 19.9 pA
to−269 ± 24.6 pA (p < 0.0001, n = 14) during nicotine applica-
tion and the restingmembrane potential (measured during a brief
switch into current clamp mode) shifted to less negative values by
an average of 7.07 ± 0.89mV (p < 0.0001, n = 14) to an average
of 48.0 ± 1.98mV.
We further tested whether nicotine affects PnC giant neu-
rons directly or through the activation of interneurons. Thus,
we blocked voltage-gated calcium channels required for synaptic
transmission by bath application of 100μM cadmium. Auditory
FIGURE 3 | PnC microinfusion of TMPH, but not of MLA, into the PnC
disrupts PPI. (A) Intracranial microinfusions of the α7 preferring nicotinic
antagonist MLA into the PnC in doses as indicated does not significantly
affect PPI at any ISI. Local MLA infusion has also no significant effect on
the baseline startle amplitude (n = 6 rats). (B) Intracranial microinfusions of
TMPH significantly disrupted PPI at the highest dose tested. The effect was
restricted to short ISIs of 20 and 50ms. TMPH did not affect the baseline
startle (n = 10 rats).
and trigeminal stimulation was used to verify the block of synap-
tic transmission. There was no significant effect of cadmium on
the membrane resistance, as shown in Figure 5 (p = 0.75; n = 9).
However, even during the blockage of synaptic transmission with
cadmium, nicotine significantly reduced themembrane resistance
of PnC giant neurons to 75± 5.9% of its original value to an aver-
age of 126± 10.47M (p = 0.03; n = 9), indicating that nicotine
either activates receptors that are directly located on the recorded
neurons, or it activates the presynaptic release of inhibitory neu-
rotransmitter independently from the activation of voltage-gated
calcium channels.
In the following experiments we aimed to confirm that the
observed nicotine effect is due to specific activation of nAChR in
the PnC. We have previously shown that the non-specific cholin-
ergic agonist carbachol inhibits PnC giant neurons and that this
inhibition is only partly reversed by specific muscarinic blockers
(Bosch and Schmid, 2006). We therefore tested, whether the spe-
cific nicotinic blocker tubocurarine reverses the inhibitory action
of carbachol on PnC giant neurons. We added carbachol (10μM)
and tubocurarine (50μM) to the bath solution. Tubocurarine is
known to be effective specifically on neuronal nAChR at con-
centrations used in this study (Jensen et al., 2005). Carbachol
significantly decreased trigeminally evoked EPSC amplitudes to
42.60 ± 3.84% of the control amplitude and auditory evoked
EPSCs to 39.23 ± 4.02% of the control amplitude (p < 0.001 in
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FIGURE 4 | Nicotine affects synaptic transmission andmembrane
resistance in PnC giant neurons. (A) Trigeminally evoked excitatory
synaptic currents in control conditions, during perfusion with nicotine and
after wash out. The asterisks mark the stimulus artifacts. Bars indicate 25ms
(horizontal) and 100 pA (vertical). 10μMNicotine significantly reduced EPSC
amplitudes following trigeminal and auditory stimulation. This effect was
reversed after wash out (n = 14 cells). (B)Whole-cell membrane leak current
amplitudes in response to 10mV step hyper- and depolarisations from
−70mV to the indicated potentials. Current amplitudes were increased
during nicotine perfusion, indicating a lower membrane resistance (top).
Calculated membrane resistances (Rm = Vm/I) show that nicotine
significantly reduces membrane resistance in PnC giant neurons (bottom).
(C) Time course showing whole-cell leak current amplitudes in response to a
depolarizing 10mV voltage step from −70mV in an exemplary cell before,
during, and after nicotine bath application (top), and the corresponding EPSC
amplitudes in the same cell (bottom).
both cases; n = 14; Figures 6A,B). Please note that the inhibition
of EPSCs by carbachol was much stronger than the inhibition of
EPSCs by nicotine shown above in Figure 3. Tubocurarine had
no significant effect on EPSCs when given alone (p = 0.9 for
both trigeminal and auditory stimulation; n = 10; Figure 5B).
Perfusion of slices with tubocurarine, however, significantly
reduced the inhibitory effect of carbachol. EPSC amplitudes
were only reduced to 67.15 ± 4.86% of control amplitudes fol-
lowing trigeminal stimulation, and 56.19 ± 3.49% of control
amplitudes following auditory stimulation (p < 0.001 in both
cases; n = 10, Figure 6A). Furthermore, carbachol significantly
decreased the membrane resistance to 69.58 ± 4.50% of con-
trol. The effect on membrane resistance was completely reversed
by the additional application of tubocurarine [F(2, 31) = 12.996;
p = 0.001; Figure 6B]. Post-hoc Tukey adjustment revealed a sig-
nificant difference between tubocurarine alone (98.91 ± 2.71%
FIGURE 5 | The nicotine effect persists in presence of cadmium.
Auditory and trigeminally evoked EPSCs were completely blocked by bath
application of 100μM cadmium, see insert (horizontal bar indicates 25ms
and vertical bar100 pA.) The effect of nicotine on the membrane resistance
in PnC giant neurons persists in presence of 100μM cadmium, indicating
that it does not require synaptic transmission. Asterisk marks statistical
significance with p < 0.05 (n = 9 cells).
of control) and carbachol alone condition (p = 0.001); and also
between carbachol and carbachol plus tubocurarine condition
(p = 0.011). In summary, tubocurarine only partly reversed the
carbachol effect on EPSC amplitude, while it completely blocked
the carbachol effect on membrane resistance. This indicates that
carbachol activates both muscarinic and nicotinic receptors, but
that its effect on the membrane resistance of PnC giant neuron is
exclusively mediated by nicotinic receptors.
In order to determine the nAChR subtype responsible for the
nicotine effect on PnC giant neurons we recorded under control
conditions, and then added the α7nAChR preferring antagonist
MLA (100 nM). After recording in presence of MLA, we added
nicotine (10μM) in order to see whether the nicotine effect is
blocked in presence of the antagonist. There was a significant
effect of drug on membrane resistance [F(2, 18) = 4.45, p = 0.02;
n = 4] and the post-hoc analysis revealed no effect of MLA alone
(101 ± 3.9%; p = 0.13), and a significant effect of nicotine in the
presence of 100 nMMLA (60± 5%; p = 0.001; Figure 7A). There
was also a significant drug effect on EPSC amplitudes [F(2, 18) =
4.5; p = 0.03; n = 4]. MLA alone did not change EPSCs (99.8
± 2.7%; p = 0.13), but the nicotine effect persisted in presence
of MLA, such that EPSC amplitudes decreased to 70 ±5% (p =
0.001; Figure 7A).
We also applied the highly specific α7 agonist PHA 543-
613 (30μm). The membrane resistance was unaffected by
the perfusion of PHA with the resistance changing to 98
± 2.1% from 192 to 189 M (p = 0.69; n = 6). EPSC
amplitudes were also unaffected by PHA (p = 0.21; n = 4;
Figure 7B). We then tested the non-α7 preferring nAChR
antagonist 2,2,6,6-Tetramethylpiperidin-4-yl heptanoate (TMPH
hydrochloride, 100 nM) using the same experimental procedure
Frontiers in Behavioral Neuroscience www.frontiersin.org February 2015 | Volume 9 | Article 30 | 6
Pinnock et al. Nicotine and PPI
FIGURE 6 | Tubocurarine partly reverses the effect of carbachol on PnC
giant neurons. (A), top: Exemplary traces of trigeminally evoked synaptic
currents during perfusion of tubocurarine, carbachol, and the two drugs
combined. Bars indicate 25ms (horizontal) and 100 pA (vertical). Bottom:
The perfusion of 50μM tubocurarine had no effect on synaptic currents,
whereas 10μM carbachol significantly reduced synaptic current amplitudes.
When tubocurarine application was combined with carbachol, the reduction
of synaptic currents was significantly smaller than with carbachol alone
(n = 10 cells for tubocurarine and tubocurarine plus carbachol, n = 14 cells
for carbachol alone). Significant differences to control are labeled by “a,”
significant differences to the carbachol condition are labeled by “b.” (B)
Membrane resistance (Rm) normalized to the resistance of each cell under
control condition. Tubocurarine had no effect on Rm, whereas the
application of carbachol significantly decreased Rm. The additional
application of tubocurarine completely reversed this effect (n = 10 cells).
as with MLA. We found no significant effect of drugs on the
membrane resistance, indicating that pre-application of TMPH
blocked the nicotine effect [F(2, 16) = 2.41; p = 0.15; n = 6].
We also found no significant drug effect on EPSC amplitudes
[F(2, 16) = 2.31; p = 0.19; n = 6; Figure 7C].
In summary, our electrophysiological experiments support
our behavioral results showing that the non-α7nAChR preferring
antagonist TMPH blocks a portion of the cholinergic inhibition
of startle neurons in the PnC, whereas the α7 antagonist MLA and
FIGURE 7 | The effect of nicotine on PnC giant neurons is mediated by
non-α7-nicotine receptors. (A) Effect of the α7nAChR preferring
antagonist MLA (100 nM). Membrane resistance (Rm) was normalized to
the resistance of each cell under control conditions. MLA alone had no
effect on Rm, however, the effect of nicotine persisted in presence of MLA.
MLA alone did also not affect EPSC amplitudes, whereas nicotine reduced
synaptic currents in presence of MLA (n = 4 cells, only trigeminal EPSC
amplitudes were analyzed). (B) Effect of the α7 specific agonist
PHA543-613 (30μM) on Rm and EPSC amplitudes: PHA 543-613 had no
effect on PnC giant neurons (n = 6 and n = 4, respectively). (C) Effect of
the non-α7 preferring antagonist TMPH (100 nM): TMPH alone had no
effect on Rm or EPSC amplitudes. In presence of TMPH, nicotine did also
not affect Rm and synaptic currents, indicating that TMPH antagonizes the
nicotine effect. Asterisk marks statistical significance with p < 0.05
(n = 6 cells).
the agonist PHA543-613 had no effect. Together with the behav-
ioral results reported above our data indicate that non-α7nAChRs
are expressed in the PnC and inhibit startle signaling, thereby
contributing to PPI at 20–100ms interstimulus intervals.
ARE NON-α7nAChRs IN THE PnC RESPONSIBLE FOR ENHANCEMENT
OF PPI THROUGH SYSTEMIC NICOTINE?
Numerous studies have shown that acute systemic nicotine
enhances PPI. We confirmed this PPI enhancing effect in our lab-
oratory, using a low intensity prepulse of 75 dB. Subcutaneous
(s.c.) injections of nicotine significantly affected PPI [F(3, 29) =
14.63; p < 0.0001; n = 8 animals; Figure 8A]. A LSD post-hoc
analysis revealed that doses of 0.01 and 0.1mg/kg had little effect,
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FIGURE 8 | Systemic nicotine enhances PPI, which can be reversed by
systemic MLA, but not by systemic TMPH. (A) Subcutaneous injections of
nicotine significantly enhanced PPI of startle at the highest dose of 1mg/kg,
without changing the baseline startle amplitude (n = 8 rats). A low prepulse
of 75 dB was used here. Nicotine did not significantly change baseline startle
responses. (B) Another batch of rats injected with 1mg/kg nicotine also
showed nicotine enhanced PPI (significant difference between saline and
nicotine condition labeled by “a”). An additional intraperitoneal injection of
5mg/kg MLA, but not of 5mg/kg TMPH or saline, significantly reduced the
nicotine enhanced PPI (significant difference between nicotine and nicotine +
MLAcondition labeledby“b”). Therewasnodrugeffecton thebaselinestartle
response (n = 8 animals). (C)With a shorter protocol and only one nicotine
injection per rat, subcutaneous nicotine at the dose of 0.1mg/kg significantly
enhanced startle at short ISIs of 12 and 20ms. This was completely reversed
by 1mg/kg MLA administered i.p., and partly reversed by 10mg/kg MLA i.p.
Asterisk marks statistical significance with p < 0.05 (n = 12 animals).
showing a significant increase in PPI only at an ISI of 250ms
with the higher dose. Systemic injections of 1mg/kg nicotine (free
base) significantly increased PPI from ∼50 to 80% for ISIs of
12, 20, 100, and 250ms. Baseline startle amplitudes were not
significantly affected by s.c. nicotine, when compared to saline
controls (n = 8; p = 0.25; Figure 8A). Testing of the higher dose
of 10mg/kg was abandoned, since it occasionally led to seizures.
After establishing the nicotine enhancement of PPI, we com-
bined systemic nicotine injections with systemic injections of
subtype-specific antagonists in a different batch of rats in order
to see whether or not the non-α7nAChRs that contribute to PPI
are also responsible for the nicotine enhanced PPI. A low pre-
pulse of 75 dB was also used here to allow for PPI enhancement by
nicotine. There was a significant effect of drug [F(2, 21) = 50.27;
p < 0.0001; n = 8; Figure 8B]. LSD post-hoc again confirmed a
PPI enhancing effect of nicotine. Further, systemic MLA, but not
TMPH, significantly attenuated nicotine enhanced PPI at ISIs of
12 and 20ms. There were no significant effects of either TMPH
or MLA on baseline startle amplitudes, in comparison to saline
controls (p = 0.15).
In a different batch of rats we repeated the MLA injections
using different concentrations. In order to avoid the possibil-
ity that nicotine receptor up- or down-regulation affects our
results, each rat received only one dose of nicotine and a saline
control injection (pseudorandomized). We also measured PPI at
ISIs of 12, 20, 100ms only, cutting down the total time of star-
tle testing in order to avoid the possibility that the short-lasting
nicotine effect was wearing off during testing. With a shorter pro-
tocol and a single dose per rat the effect of the lower dose of
0.1mg/kg nicotine was also significant. Co-administration of 1
and 10mg/kg MLA reversed the PPI enhancing effect of nicotine
in a dose dependent manner (Figure 8C). ANOVA revealed an
effect of drug [F(3, 56) = 5.17; p = 0.003; n = 12] and post-hoc
tests showed a significant effect of nicotine for the nicotine only
measurements at 12ms (p = 0.003) and 20ms ISI (p = 0.04),
but no significant change to saline control when MLA was co-
administered, except from the less efficient MLA dose at 20ms ISI
(Figure 8C). Systemic TMPH tested at these conditions had still
no effect on nicotine enhanced PPI [F(3,56) =0.173; p = 0.916;
n = 12; data not shown]. In summary, nicotine enhanced PPI
seems to be dependent on α7nAChRs. Our previous in vivo
and in vitro results indicated that nAChRs expressed in the PnC
are of the non-α7nAChR type, since neither the α7nAChR ago-
nist PHA 543-613 nor MLA applied to the PnC revealed any
effect on PnC signaling or PPI (see above). In accordance with
this, local microinfusions of MLA into the PnC did not affect
nicotine enhanced PPI [F(1, 23) = 2.21, p = 0.34; n = 12 ani-
mals; Supplementary Figure S3] or baseline startle (p = 0.81;
n = 12; data not shown). In summary, systemic antagonism of
α7nAChRs, but not local antagonism in the PnC, reversed the PPI
enhancing effect of nicotine.
In conclusion, our present study indicates that nAChRs are
functionally expressed in the PnC, which receives cholinergic
input from the PPT. Both electrophysiological and behavioral
data suggest that these are non-α7nAChRs and that they are acti-
vated during PPI, contributing to the inhibition of startle by
prepulses. In contrast, the enhancement of PPI through systemic
nicotine is mediated by α7nAChRs expressed elsewhere in the
brain than in the PnC.
DISCUSSION
In order to identify the role of nAChRs in PPI, we employed
systemic injections and stereotaxic microinfusions in combina-
tion with behavioral measurements and in vitro slice electro-
physiology. Our studies suggest that non-α7nAChRs in the PnC
contribute to startle inhibition by prepulses, whereas the PPI
enhancing effect of systemic nicotine is mediated predominantly
by α7nAChRs that are not located in the PnC.
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nAChRs IN THE PnC
Stereotaxic microinfusions into the PnC as well as our elec-
trophysiological experiments clearly showed the expression of
functional nAChRs in the PnC. The fact that local microinfu-
sion of both nicotine and the nicotine antagonist TMPH into the
PnC inhibited PPI seems puzzling at first glance; however, the
presence of exogenous nicotine presumably makes these recep-
tors unavailable for additional activation by acetylcholine released
from PPT projections, therefore nicotine basically acts as an
antagonist. Alternatively, the persistent presence of a high con-
centration of nicotine following PnC microinfusion could also
simply inactivate nAChRs (Revah et al., 1991). We saw no sign of
a decay of nicotine effect on PnC neuron excitability during the
10min. nicotine bath application, which favors the first possibil-
ity. However, we would expect to see a reduction of baseline startle
after local nicotine microinfusion due to reduced PnC excitability,
which we did not find. Baseline startle amplitudes, though, can
be very variable and e.g., potentiated by the microinfusion pro-
cedure itself, since it is mildly stressful and might lead to startle
sensitization.We therefore, might havemissed changes in baseline
startle.
Our findings are in line with results of Stevens et al. (1993)
who showed an antagonistic effect of tubocurarine on nicotine
induced effects on postsynaptic currents of medial pontine retic-
ular formation neurons. A previous study showed that activation
of muscarinic receptors in the PnC inhibits synaptic transmis-
sion presumably through a presynaptic mechanism (Bosch and
Schmid, 2006). We found an additional non-muscarinic receptor
mediated effect of carbachol that affected the membrane resis-
tance of PnC neurons (Bosch and Schmid, 2006, 2008). Our
present data using carbachol in combination with tubocurarine
further indicates that there is a nicotinic component contribut-
ing to the effect of carbachol on PnC neuron signaling, and
that this nicotinic component is not affecting presynaptic gluta-
mate release. Nicotine receptors are known to be cation chan-
nels that activate and inactivate rapidly. Neither our nicotine
microinfusions, nor the bath application of nicotine are suit-
able to capture any of these rapid and short-lasting effects of
nicotine receptor activation. Instead, we observe a tonic effect
of startle-mediating PnC neurons through nicotine that reduces
the membrane resistance and EPSC amplitudes while shifting
the resting membrane potential toward less negative values. It
has to be noted that since we didn’t correct our data for the
liquid junction potential, the measured resting membrane poten-
tial of −48mV during nicotine application may correspond to
a real membrane potential of around −60mV. The observed
nicotine effects are independent from the activation of cadmium
sensitive voltage-gated calcium channels commonly required for
neurotransmitter release. Also, it doesn’t affect paired-pulse ratio
of the glutamatergic EPSCs. Together, this suggests that nico-
tine does not affect presynaptic glutamate release probability.
Future studies will have to show whether calcium influx through
nAChRs directly activates presynaptic glycine or GABA release
onto PnC giant neurons, and/or whether postsynaptic nAChRs
affect PnC excitability through e.g., the activation of potassium,
cation and/or chloride channels (for review see Shen and Yakel,
2009).
TIMING
Our present and past studies show the functional expression of
both muscarinic and nicotinic receptors in the PnC, the sen-
sorimotor interface of the startle circuitry. Microinfusion of
nicotine and TMPH into the PnC in our study, as well as of
muscarinic antagonists by Fendt and Koch (1999), significantly
attenuated PPI, indicating that the activation of both muscarinic
and nAChRs are likely contributing to PPI of startle. The generally
limited effects of cholinergic antagonists indicate that the cholin-
ergic inhibition might not be restricted to the PnC, but also affect
sensory neurons upstream (Gómez-Nieto et al., 2014), and that
other neurotransmitters, such as GABA, glutamate, and glycine,
also contribute to PPI, as proposed before (Yeomans et al., 2010;
Geis and Schmid, 2011).
Both ionotropic andmetabotropic cholinergic and GABAergic
receptors mediate PPI in rats (Jones and Shannon, 2000b;
Yeomans et al., 2010, present data). Ionotropic receptors within
the primary startle and PPI pathway would be expected to medi-
ate PPI at rather short ISIs, due to their rapid activation and
inactivation. In particular, α7nAChRs and GABAA receptors have
been shown to be most important for PPT at ISIs roughly from
20–100ms (Figures 2, 3; Yeomans et al., 2010). Muscarinic recep-
tors are slower to activate and yield longer lasting effects and
should therefore, affect PPI at intermediate and longer ISIs.
Indeed, it has been shown that systemic injections of GABAB
or muscarinic antagonists disrupt PPI at longer ISIs from 100–
500ms, but not at short ISIs (Jones and Shannon, 2000b; Fendt
et al., 2001; Ukai et al., 2004; Yeomans et al., 2010), and PnC
microinfusion of muscarinic antagonists as well as knock-out of
muscarinic M4 receptors have been shown to disrupt PPI in rats
at ISIs of 100ms (Fendt and Koch, 1999; Koshimizu et al., 2012).
This clearly corroborates the hypothesis that the serial activation
of ionotropic and metabotropic receptors contribute to the fast,
transient and the long lasting inhibition of startle by a prepulse,
respectively.
SOURCE OF ACETYLCHOLINE
The mesopontine cholinergic projections from the pedunculo-
pontine tegmentum (PPT) to the startle mediating giant neurons
in the caudal pontine reticular nucleus (PnC) have been identified
as a crucial structure for inhibiting startle during PPI (for review
see Koch, 1999; Fendt et al., 2001). In general, the mesopon-
tine cholinergic cell groups send mainly ascending projections to
the collicullus, thalamus, and striatum promoting orienting and
approach behavior, as well as eye saccades, while the descend-
ing projections seem to inhibit avoidance/escape responses (Fendt
et al., 2001; Jones and Shannon, 2004; Mena-Segovia et al.,
2008; Winn, 2008; Yeomans, 2012). Stimulation of the PPT has
shown to increase acetylcholine release in the PnC (Lydic and
Baghdoyan, 1993), however, based on our data we cannot assume
that the only source of acetylcholine release in the PnC is the PPT
projection. Lesions the adjacent laterodorsal tegmentum (LDT)
has also been shown to disrupt PPI (Jones and Shannon, 2004),
whereas in a recent study specific cholinergic lesions in the PPT
almost completely abolished startle responses without necessarily
impacting PPI (MacLaren et al., 2014). This indicates that either
the LDT is directly involved in mediating PPI or that there is a
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more complex cholinergic regulation of PnC inhibition on the
level of LDT/PPT (see Kohlmeier et al., 2012).
Interestingly, our finding of fast nicotinic receptor activation
followed by slower muscarinic activation parallels results shown
for other PPT/LDT outputs, e.g., to the colliculus as shown in
monkeys and rats (Isa and Hall, 2009), or to the thalamo-cortical
arousal system for improving sensory processing in cats and rats
(Steriade, 1993).
nAChR SUBTYPES
Nicotine receptor modulators, especially of the α7nAChR sub-
type, are currently evaluated in many studies as a potential target
for enhancing cognitive function (Young and Geyer, 2013; Young
et al., 2013). Both major nAChR subtypes found in the mam-
malian brain, the α4β2 and/or α7, were reported to be involved
in PPI or in other forms of sensory gating (for review see Adler
et al., 1998; Schreiber et al., 2002; Leiser et al., 2009). Our elec-
trophysiological and behavioral data indicate that the nAChRs
in the PnC are mainly of the non-α7 subtype since the non- α7
preferring antagonist TMPH reversed nicotine effects, whereas
the α7 specific antagonist MLA and agonist PHA 546613 had
no effect. TMPH antagonizes the majority of subtypes found in
non-α7 containing neural nAChRs, which include the α3, α4, β2,
and β4 subunits (Damaj et al., 2005). The α4β2 nAChR subtype
is the most common neuronal non-α7nAChR and it has been
shown to be involved in cognitive processing (Changeux, 2010).
It is therefore, the most likely candidate for mediating ionotropic
cholinergic effects in the PnC, but further research is required to
confirm this.
The involvement of non-α7nAChR is surprising, since the
α7nAChR has been implicated in the past in PPI and cogni-
tive function: Specific α7nAChR agonists have been shown to
ameliorate sensory gating deficits (Adler et al., 1998; Stevens
et al., 1998; Suemaru et al., 2004; Kohnomi et al., 2010), and
α7nAChR knock-out mice show a mild PPI deficit in a recent
study (Azzopardi et al., 2013), although previous studies had not
reported any PPI deficits in these mice (Paylor et al., 1998; Young
et al., 2011). However, our data indicate that non-α7nAChRs
in the PnC contribute a small portion to normal PPI, whereas
α7nAChRs elsewhere in the brain can exert a powerful mod-
ulation of PPI when activated e.g., by exogenous nicotine (see
below).
SYSTEMIC NICOTINE ENHANCED PPI
Previous studies have shown that systemic nicotine or nicotine
agonists enhance PPI in rats (Acri et al., 1994; Curzon et al., 1994;
Faraday et al., 1999; Schreiber et al., 2002). Our data extend this
result by showing that a low dose of nicotine increased PPI at an
ISI of 250ms, whereas a higher dose of nicotine was more effec-
tive in enhancing PPI at shorter ISIs (between 12 and 50ms),
where maximum PPI is observed in rats. Both the timing of the
systemic effect of nicotine, as well as the fact that systemic MLA,
but not PnC microinfusions of any nicotine antagonists, reversed
the systemic nicotine effect, indicate that systemic nicotine pre-
dominantly affects α7nAChR nAChRs in brain regions other than
the PnC that extrinsically modulate PPI. Indeed, multiple brain
areas that have been shown to modulate PPI (for review see Koch,
1999; Fendt et al., 2001), receive cholinergic input, and express
α7nAChRs, which include the superior colliculus, thalamus, basal
lateral amygdala, the substantia nigra (SN), the hippocampus,
the striatum, and the medial prefrontal cortex (mPFC, Woolf,
1991). Most importantly, Azzopardi et al. (2013) has shown that
α7nAChR knock-out mice do not show nicotine enhanced PPI,
which is in accordance to our current pharmacological results in
rats.
Almost all individuals with schizophrenia smoke cigarettes and
show improvement in cognitive performance and normal PPI fol-
lowing nicotine consumption (Kumari et al., 1996; Forchuk et al.,
1997; Adler et al., 1998; Postma et al., 2006). Our results indi-
cate that this effect may be due to the activation of α7nAChRs.
Interestingly, the α7 subunit of the nAChR has been identified as a
susceptibility gene for schizophrenia (for review see Martin et al.,
2004).
CONCLUSION
In conclusion, the present study shows that activation of non-
α7nAChRs in the PnC contributes a small, but significant portion
to PPI at short interstimulus intervals, whereas activation of
α7nAChRs elsewhere in the brain predominantly mediate the
PPI enhancing effect of an acute dose of nicotine. This is an
important piece in understanding not only the role of choliner-
gic neurotransmission in arousal, orienting responses and startle
inhibition, but also for the correct interpretation of behavioral,
preclinical, and clinical data as well as for developing drugs for
the amelioration of PPI deficits and the enhancement of cognitive
function.
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